Oncocyte Return on Equity

Oncocyte (OCX) currently reports a ROE of 4.47%. That is above the Technology sector average of 47.22%. Use the charts on this page to explore Oncocyte's ROE history and peer comparisons.

Oncocyte's ROE of 4.47% is higher than the Technology sector average of 47.22%. That is roughly 847.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Oncocyte's current 4.47% should be judged against Technology norms (sector average: 47.22%) and against OCX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 4.47%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 47.22%. From there, open related valuation or income-statement pages for Oncocyte, and consider following OCX for alerts when major investors trade the stock.

Oncocyte is classified in the Technology sector. On ROE, it currently shows 4.47% versus a sector average near 47.22%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing OCX with unrelated industries.